Entering text into the input field will update the search result below

NanoString and RikenGenesis inks deal to commercialize nCounter-based diagnostic assays in Japan

  • NanoString Technologies (NASDAQ:NSTG) and Riken Genesis, a subsidiary of Sysmex Corporation have entered into a partnership to introduce nCounter-based diagnostic assays in Japan.
  • Under this agreement, NanoString and Riken will collaborate to register, obtain reimbursement and commercialize companion diagnostic assays in Japan, including NanoString’s Lymphoma Subtyping Test which will be marketed as the nCounter Dx LymphMark assay.
  • Financial terms are not disclosed.
  • LymphMark is a 20-gene signature that classifies cell-of-origin subtypes of Diffuse Large B-cell Lymphoma tumors.

Recommended For You

More Trending News

About NSTGQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NSTGQ--
NanoString Technologies, Inc.